Adipose derived mesenchymal stem cell therapy - Cell2Cure
Alternative Names: C2C_ASC; Cell2Cure®Latest Information Update: 10 Oct 2024
Price :
$50 *
At a glance
- Originator Cell2Cure ApS
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Sjogren's syndrome
- Phase I Diabetic foot ulcer; Gastrointestinal disorders; Pervasive child development disorders
Most Recent Events
- 20 Sep 2024 Cell2Cure ApS completes a phase I trial in Pervasive child development disorders and Gastrointestinal disorders (In children, In adolescents) in Denmark (IV) (NCT05602116)
- 09 Jun 2023 Phase-I clinical trials in Gastrointestinal disorders (In children, In adolescents) in Denmark (IV) (NCT05602116)
- 09 Jun 2023 Phase-I clinical trials in Pervasive child development disorders (In children, In adolescents) in Denmark (IV) (NCT05602116)